Chemotherapy and targeted treatments of breast sarcoma by histologic subtype.

Details

Serval ID
serval:BIB_A06BD9846D13
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Chemotherapy and targeted treatments of breast sarcoma by histologic subtype.
Journal
Expert review of anticancer therapy
Author(s)
Kokkali S., Stravodimou A., Duran-Moreno J., Koufopoulos N., Voutsadakis I.A., Digklia A.
ISSN
1744-8328 (Electronic)
ISSN-L
1473-7140
Publication state
Published
Issued date
06/2021
Peer-reviewed
Oui
Volume
21
Number
6
Pages
591-604
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
Introduction: Breast sarcomas (BS) are uncommon and often present both diagnostic and therapeutic challenges. Historically, radical surgery has been the mainstay of treatment for localized breast sarcomas. On the other hand, in advanced disease, since they are a heterogeneous group of neoplasms consisting of several different subtypes including angiosarcoma, phyllodes tumor, and pleomorphic undifferentiated sarcoma, there is a lack of proven specific therapy. As a result, their treatment is based on the soft tissue sarcoma (STS) paradigm, whereas histotype-tailored approaches apply to specific subtypes like dermatofibrosarcoma protuberans. To date, advanced stages constitute an incurable form of disease and chemotherapy remains the cornerstone of treatment with the aim of palliation of symptoms and increase in survival.Areas covered: In this manuscript, we review the clinicopathologic characteristics of the most common subtypes of BS, as well as the current treatment landscape of BS, with a particular focus on opportunities and challenges provided by new targeted molecules and immunotherapy.Expert opinion: The treatment approach of advanced BS is based on the pathologic subtype. A true breakthrough has still to be obtained, as the development of new agents in BS suffers from the same weaknesses as in other STS.
Keywords
Advanced, Angiosarcoma, Breast, DFSP, Immunotherapy, Phyllodes, Sarcoma, Treatment, angiosarcoma, breast, immunotherapy, phyllodes, treatment
Pubmed
Web of science
Create date
22/02/2021 14:22
Last modification date
23/10/2021 5:38
Usage data